Status:
COMPLETED
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
Lead Sponsor:
Dennis Charney
Conditions:
Mood Disorder
Anxiety Disorders
Eligibility:
MALE
25-45 years
Phase:
PHASE2
Brief Summary
There is growing evidence that neuropeptides act as neuronal messengers in the brain and have diverse functions that may include the regulation of mood and behavior. For example, neuropeptide Y (NPY) ...
Detailed Description
There is growing evidence that neuropeptides, including neuropeptide Y (NPY), act as neuronal messengers in the brain and have diverse neurobehavioral functions. Their therapeutic application for psyc...
Eligibility Criteria
Inclusion
- Men aged 25-45.
- No history of Axis I disorder as defined in the DSM-IV other than past nicotine abuse or dependence or adjustment disorder.
Exclusion
- Nicotine or caffeine abuse or dependence within the preceding 3 months.
- History or complaint of nasal disorders or allergies.
- Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic.
- Significant obesity (BMI \> 30), scoliosis, spinal stenosis or a history of lumbosacral laminectomy.
- Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG.
- Current use of any medications that have effects on CNS function.
- Prior sinonasal surgery, or significant nasal polyps as determined by nasal endoscopy.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00748956
Start Date
January 1 2010
End Date
January 1 2012
Last Update
August 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai School of Medicine
New York, New York, United States, 10029